The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
To be a Repligen shareholder, you need to believe in the company's ability to deliver innovative bioprocessing technologies and capture demand as new therapies reach commercialization. The recent Novasign partnership bolsters Repligen's TFF systems with machine learning, but the immediate impact may not fully address the short-term risk of muted order intake from smaller biotech clients given continued industry funding softness.
Among recent announcements, the July earnings report stands out, showing a jump in quarterly revenue to US$182.37 million and strengthened guidance. While performance improvements are promising, the partnership with Novasign arrives as the company continues to pursue process efficiency and product mix enhancement for better gross margin resilience.
Yet, despite tech advances, order visibility risk from smaller biotechs continues to be something investors should be aware of, especially if...
Read the full narrative on Repligen (it's free!)
Repligen's outlook anticipates $1.0 billion in revenue and $140.0 million in earnings by 2028. This is based on a projected 15.6% annual revenue growth rate and a $153.8 million increase in earnings from the current $-13.8 million.
Uncover how Repligen's forecasts yield a $179.72 fair value, a 48% upside to its current price.
Simply Wall St Community members see Repligen’s fair value ranging sharply from US$47.44 to US$179.72, across 4 independent perspectives. With recent tech collaborations aiming to boost efficiency, your view on sector funding risk may shape your outlook, compare different rationales for a well-rounded assessment.
Explore 4 other fair value estimates on Repligen - why the stock might be worth less than half the current price!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com